Sign up
Pharma Capital

AIM Targeted Therapies seeks $16.5mln to further develop its two products

AIM Targeted Therapies CEO Dr. Glenn Abrahmsohn joins Proactive Investors at the 11th Annual Biotech Showcase in San Francisco.

The company is developing new solutions to address opioid addiction and antimicrobial resistance.

 

View full AIMTT profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.